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1  | INTRODUC TION—B CELL TOLER ANCE 
AT THE BEGINNING
In the late 1890s Paul Ehrlich and Julius Morgenroth probably first 
recognized what today would be called "B cell tolerance." Ehrlich and 
Morgenroth were investigating the properties of serum that seemed 
to connect specificity with effector functions in immunity to patho‐
gens and toxins.1 This subject was a matter of great controversy 
and it engaged practically all of the forebears of the new field of 
immunology.1 Jules Bordet had reported that the serum of rabbits 
exposed to heterologous (guinea pig) erythrocytes acquired height‐
ened ability to agglutinate and lyse fresh guinea pig erythrocytes.2 
Some believed that the agglutination and dissolution of erythrocytes 
by serum was analogous to the agglutination and killing of bacteria, 
but Ehrlich and Morgenroth considered that the impact of serum on 
heterologous erythrocytes was not biologically relevant since in nor‐
mal circumstances rabbits are not exposed to guinea pig blood.
The biologically relevant question, Ehrlich and Morgenroth 
asserted was whether and how ones own erythrocytes are dis‐
solved and whether this process relates in any way to protective 
properties of an immune serum. This question had a rational basis 
since internal bleeding generates hematomas that "dissolve" spon‐
taneously over a period of weeks. It was to test the biological 
relevance of Bordet's observations for the formation and dissolu‐
tion of hematomas that Ehrlich and Morgenroth conducted what 
in retrospect were the seminal experiments on B cell tolerance.1 
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Abstract
B cell tolerance has been generally understood to be an acquired property of the 
immune system that governs antibody specificity in ways that avoid auto‐toxicity. 
As useful as this understanding has proved, it fails to fully explain the existence of 
auto‐reactive specificities in healthy individuals and contribution these may have to 
health. Mechanisms underlying B cell tolerance are considered to select a clonal rep‐
ertoire that generates a collection of antibodies that do not bind self, ie tolerance 
operates more or less in three dimensions that largely spare autologous cells and 
antigens. Yet, most B lymphocytes in humans and probably in other vertebrates are 
auto‐reactive and absence of these auto‐reactive B cells is associated with disease. 
We suggest that auto‐reactivity can be embodied by extending the concept of toler‐
ance by two further dimensions, one of time and circumstance and one that allows 
healthy cells to actively resist injury. In this novel concept, macromolecular recogni‐
tion by the B cell receptor leading to deletion, anergy, receptor editing or B cell acti‐
vation is extended by taking account of the time of development of normal immune 
responses (4th dimension) and the accommodation (or tolerance) of normal cells to 
bound antibody, activation of complement, and interaction with inflammatory cells 
(fifth dimension). We discuss how these dimensions contribute to understanding B 
cell biology in health or disease.
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To model hematoma formation and to provide a maximum stim‐
ulus for generation of "lysins" Ehrlich and Morgenroth injected 
800‐900 ml of blood from one or more of nine goats into the peri‐
toneum of five normal goats and they tested the sera of the in‐
jected goats for ability to lyse erythrocytes from the nine "donors" 
at various times thereafter.
The results of the experiment were striking. The serum of one 
goat, which had been injected with a mixture of blood from goats 
#1, #2, and #3, exhibited "strong" lytic activity against erythro‐
cytes from goat #1 and goat #2, but notably less lytic activity 
against goat #3. The serum also exhibited lytic activity against 
erythrocytes from goats #4, #5, #6, and #9, but less against goat 
#8 and no lytic activity against erythrocytes from goat #7. Other 
goats treated with isogeneic erythrocytes exhibited distinct pat‐
terns, intensities, and kinetics of lytic activity against isologous 
erythrocytes; ultimately, 12 distinct isolysins were identified. 
However, in all of the experiments and in every condition tested 
no autolysin was ever detected.
Ehrlich struggled to explain how goats could generate highly 
specific isolysins without ever producing autolysins, since the side 
chain theory put forward in 1897 maintained that antibodies were 
receptors for nutrients and other substances that could benefit 
cells. In the end, they concluded that production of isolysins re‐
flected "individuality" (a concept pioneered by Leo Loeb) and 
that the absence of autolysins reflected: "certain contrivances by 
means of which the immunity reaction is prevented from acting 
against the organism's own elements".1
2  | WORKING DEFINITIONS OF B CELL 
TOLER ANCE
Although the term "B cell tolerance" is commonly used, reviews on 
the subject not infrequently omit a definition of B cell tolerance. 
For some, the definition of B cell tolerance may be so obvious that 
any statement of it would be unnecessary or even condescending. 
For some others, a definition of B cell tolerance might be "difficult 
to put intelligibly" as a famous American jurist explained omission 
of another definition, adding: "but, I know it when I see it".3 For still 
others, straight‐forward definitions of B cell tolerance inevitably 
fail to explain why all normal individuals have a preponderance of 
auto‐reactive antibodies and B cells in primary antibody and B cell 
repertoires but lack overt manifestations of autoimmune disease, 
despite the many infectious and inflammatory challenges met dur‐
ing their lives.
If definitions of B cell tolerance are avoided today, definitions 
have been offered, courageously, in the past. Reflecting on the 
discovery of B cell tolerance as a distinct biological phenomenon, 
Brent 4 describes B cell tolerance as an acquired state of the im‐
mune system characterized by "specific unresponsiveness." This 
working definition advances well beyond the view of Ehrlich and 
Morgenroth, to envision B cell tolerance as: (a) specific; (b) acquired; 
and (c) a property of the immune system. These characteristics of 
tolerance remain are widely embraced if not central to the canons 
of modern immunology. Yet, each element of this definition is sub‐
ject to challenge by observations made in recent decades. Below we 
describe some understandings about the nature of B cell tolerance 
and exceptions thereof and we offer several further "dimensions" 
that help align the canonical concept of B cell tolerance with normal 
physiology (Figure 1).
3  | B CELL TOLER ANCE IN THREE 
DIMENSIONS
If Ehrlich's seminal experiments proved anything besides the exist‐
ence of contrivances that prevent immunopathology, it was that 
antibody recognition could be extraordinarily specific and diversity 
potentially greater than theory provided. Ehrlich had already con‐
cluded that that antibody and antigen might fit each other like a key 
in a lock (a metaphor borrowed from Emil Fischer 5). The idea that 
paratope binding to epitope more or less requires three dimensional 
fit still dominates teaching and investigation in immunology. The idea 
that the specificity of antibody and hence B cell recognition derives 
to a considerable extent from the three dimensional interaction of 
paratope and epitope traces to the lock and key model and that met‐
aphor is still used to describe some antibody‐antigen interactions.6,7
Despite the heuristic appeal of the lock and key model, interac‐
tions between antibodies and antigens, particularly paratopes with 
epitopes, are far more complex than the static, inert image a lock 
and key conveys. The three dimensional structures of antibodies do 
appear to fit some antigens, but forces never imagined in the original 
model govern the rate and extent or association and the permanence 
of binding. For example, electrostatic interaction and conforma‐
tional motion govern association of some antibodies with antigens 
8 and hydrophobic interactions and conformational flexibility the 
dissociation of some antibodies with antigens.9,10 Induced fit of anti‐
body and antigen likewise deviates from the classical concept. These 
complexities, however, need not detract from the idea that antibody 
and antigen combine in three dimensions.
What matters from a biological perspective is that the set con‐
ditions that enable antibodies to bind antigen with specificity and 
avidity must govern interactions between the BCR and antigen. If in‐
teractions of BCR with antigen departed from antibody interactions 
with antigen, B cell activation, affinity maturation, and receptor ed‐
iting would generate some antibodies that are less effective in con‐
ferring protective immunity and some antibodies that inadvertently 
bind autologous cells or macromolecules. Thus, the generation and 
policing of tolerance by clonal deletion, anergy, and receptor editing 
depend on the fitting of BCR and antibody paratope with epitope in 
three dimensions, however complex as that fitting may be.
The three dimensional model underscores a potentially import‐
ant challenge—effective induction of immunity and tolerance may 
depend on delivery to lymphoid organs of antigens faithfully rep‐
resenting the structure and surrounding microenvironment of anti‐
gen in microorganisms or in the body. This potential requirement is 
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well‐recognized as a key barrier to generating protective antibodies 
(especially broadly neutralizing antibodies) to HIV and some other 
infectious agents.11 Accordingly, (i) simple polypeptide vaccines 
against HIV do not generate protective immunity, instead the anti‐
gen needs (a) correct 3‐dimensional structure; (b) membrane Virus 
Like Particles (VLPs) to recapitulate the biochemical environment in 
which the antigen must be recognized, (c) other factors such as anti‐
genic evolution also need to be taken into consideration.11 Similarly, 
a requirement for delivery of antigens in native conformation and/
or in the context of surrounding microenvironment to bone marrow 
or lymphoid organs has been given little consideration in the gener‐
ation of tolerance.
Under the current model of tolerance, B cells that bind self‐an‐
tigens engage regulatory mechanisms that reduce/abolish self‐re‐
activity. These mechanisms consist of deletion (when the antigen is 
membrane bound 12), anergy (when the antigen is in a soluble state 
13,14), or by receptor editing in which ongoing immunoglobulin (Ig) 
light chain gene recombination alters the B cell antigen specificity 
and in so doing rescues the auto‐reactive B cell from deletion, 15‐18 
(reviewed in 19). The concept of anergy was expanded by Fulcher 
et al20 and by Cyster et al21 who showed that anergic B cells in the 
periphery when in competition with non‐auto‐reactive cells, are ex‐
cluded from lymphoid structures and gradually deleted. The consen‐
sus is that B cell tolerance results from deletion and receptor editing 
of developing auto‐reactive B cells and from decreased viability and/
or functionality of mature auto‐reactive B cells (for a review 22).
Immunity and tolerance to major blood groups in humans (blood 
groups A, B and O) provide insights into the precision, effectiveness, 
and limitations of tolerance in three dimensions. Synthesis of the 
blood group A and B antigens is catalyzed by glycosltransferases 
inherited as allelic variants.23 All immune competent individuals de‐
velop antibodies against blood group A and/or B antigens they do 
not produce but have no antibody in the blood against the products 
of the transferases they express.24,25 Individuals of blood type O 
produce neither group A nor group B saccharide and make natural 
antibodies against the corresponding antigens, while individuals of 
blood group A have antibodies against blood group B but not against 
blood group A.
Absence of antibodies in blood specific for autologous blood 
group antigens, might reflect self‐tolerance. However, Karl 
Landsteiner, who discovered the major blood groups at the begin‐
ning of the 20th century, long maintained that absence of antibod‐
ies against these and other autologous antigens might simply reflect 
absorption of the antibodies from blood.26 Therefore, identification 
and enumeration of B cells specific for autologous antigen could 
offer independent and potentially more incisive way to identify tol‐
erance. Rieben and colleagues27 used a limiting dilution technique 
to deduce the frequency of B cells secreting anti‐blood group an‐
tibodies in the blood of human subjects and the results were strik‐
ing. Approximately 1/10 000 produced IgM against allogeneic blood 
group A or B antigen but, <1/100 000 produced IgM that bound 
self‐blood group antigens. The results are consistent with deletion 
F I G U R E  1   The five dimensions of B cell tolerance. B cell tolerance is classically defined as an acquired state of the immune system 
characterized by "specific unresponsiveness." Viewed in this way B cell tolerance is (a) specific; (b) acquired; and (c) a property of the immune 
system. Under this model what determines immune‐pathogenicity is whether or not the B cell (and antibody) specificities exist (left panels). 
Because antibodies recognize native molecules in three dimensions this model accounts for the first three dimensions of tolerance. A fourth 
dimension posits that pathogenicity also depends on the kinetics of antibody production and on the separation of targets and blood vessels 
where most antibodies circulate. The fourth dimension explains why antibodies clearly contribute to rejection of solid organ allografts and 
not of tissues (middle panel). The fifth dimension represents resistance to immune mediated damage of cells. Tissues “adapt” to antibody 
mediated damage and to complement explaining why pathogenic antibodies do sometimes exist without causing disease. This process 
is called “accommodation” (right panel). C, complement. The circular arrow represents complement driven away from the cell surface; X, 
deletion
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by one or another mechanism, the rare B cells producing antibodies 
against self‐blood groups being recently produced or anergic.
Blood group incompatibility between a donor and recipient has 
been long considered a barrier to organ transplantation. Because 
blood group antigens are expressed also at high levels on endothelial 
cells and some epithelial cells, anti‐blood group antibodies can recog‐
nize and potentially initiate injury of organs containing endothelium 
expressing foreign blood group antigens.28 For reasons incompletely 
understood, natural immunity against allogeneic blood group anti‐
gens is not present at birth but develops in the first few months of 
life.29 Therefore, transplantation of the heart in newborn infants of‐
fers an instructive view of the acquisition of immunity and tolerance.
In newborn recipients yet to develop mature B cells specific for 
the foreign saccharides in the graft, little or no antibody against the 
saccharide is detected once the B cell response matures and few 
or no B cells specific for the saccharide in the heart are detected in 
the blood.30,31 These observations indicate that newborn recipients 
develop tolerance to the foreign blood group saccharide(s) (Figure 2). 
However, the recipients develop normal levels of antibody and nor‐
mal B cell responses to foreign saccharides not present in their 
transplant indicating that tolerance is “specific”. In mature recipients, 
tolerance to blood groups does not generally occur and recipients 
have varying amounts of antibody against the donor blood group 
detectable in blood after transplantation.
The experience in transplantation across blood groups illus‐
trates an important limitation on analysis of tolerance. When 
abundant and/or persistent antigen generates immunity, the levels 
of specific Ab at various times may not reflect the intensity of the 
immune response and the absence of antibody after effective im‐
munization could wrongly suggest the presence of tolerance. The 
underestimation of immunity and specious evidence that antibody 
production had been regulated or abolished was discussed long ago 
by Landsteiner.26 Many others have observed a decrease in specific 
antibody in blood after introduction of antigen. This phenomenon 
occurs after organ transplantation.32,33
The most important limitation of the three dimensional model 
of tolerance is that it fails to explain how a primary B cell repertoire 
consisting mainly of auto‐reactive B cells develops and persists.34
As the example of B cells specific for blood group antigens con‐
firms, antigen specific B cells can be deleted during development. 
But clearly, for some abundant and readily available antigens, central 
deletion does not occur. Deletion or receptor editing of auto‐reac‐
tive B cells might occur if BCR were to be stimulated in the absence 
of co‐stimulation,35 but potential for such stimulation should accu‐
mulate over time. We find it curious that delivery of co‐stimulation 
in the context of tissue injury, vaccination, and other aspects of daily 
life does not activate auto‐reactive B cells leading to affinity matu‐
ration and autoimmune disease. The B cells that produce antibodies 
that recognize tetanus toxoid and autoantigens, are potentially stim‐
ulated by tetanus vaccination and tetanus immunity but not autoim‐
mune disease ensues.
4  | SPACE AND TIME: A FOURTH 
DIMENSION OF B CELL TOLER ANCE
According to Ehrlich's concept of horror autotoxicus, some intrinsic 
facet of biological systems prevents autoantibodies from causing 
disease.36 Immunologists generally maintain that B cell tolerance 
prevents autoimmune disease by preventing production of autoan‐
tibodies. Therefore, the study of the mechanisms that prevent auto‐
immune disease can shed light on mechanisms of tolerance.
If this concept appears reasonable, it evades important charac‐
teristics of the normal immune system. Normal individuals produce 
F I G U R E  2   Tolerance by clonal deletion in ABO‐incompatible transplantation. Newborn infants who receive cardiac transplants from 
donors incompatible for blood group A or blood group B commonly often develop tolerance spontaneously to the foreign blood group 
antigen in the transplant. The figure depicts an example. Antibody‐secreting cells from an individual of blood group O who infancy received 
a cardiac transplant from a donor of blood group B is tested years later. The recipient has plentiful B cells that secrete antibody specific 
for blood group A (left) in ELISPOT but no B cells that secrete antibodies specific for blood group B (right). From Fan et al,30 fig. 4, with 
permission of the publisher
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at least some autoantibodies, including anti‐DNA antibodies 37 and 
rheumatoid factor detectable in the blood 38 and yet individuals with 
those antibodies often manifest no disease (Figure 3). The autoan‐
tibodies in normal individuals are considered "natural" antibodies 
because production is not preceded by an eliciting event. Natural 
antibodies that are auto‐reactive might be products of innate B1 B 
cells responding to bacterial products or might be evoked by auto‐
antigens, much as natural isoantibodies are postulated to originate 
in one or both ways.39 Although in both examples, there is no sen‐
sitizing event or evident co‐stimulus, antibody production could be 
provoked by cross‐linking BCR or by some occult, unrelated event 
that generates a second signal.
Natural IgM autoantibodies can be found in the umbilical cord 
blood in absence of exposure to any foreign antigens. They are poly‐
reactive, bind several glycoproteins, phospholipids and glycolipids 
present in membrane receptors of autologous and allogenic cells. 
Auto‐reactive natural IgM are encoded by germ line (non‐mutated) 
variable region nucleotide sequences and lack N regions (Terminal 
deoxynucleotydyl transferase, TdT, inserted random nucleotides 
during repair of V(D)J junctions).40 These properties are consistent 
with a fetal origin. Most natural autoantibodies are IgM (actually 
most IgM in normal sera are polyreactive and auto‐reactive) but 
some monovalent IgM or auto‐reactive IgG is detected.41,42
That IgM natural antibodies are protective in spite of their auto‐
reactivity has been suggested by several authors. In one mechanism, 
dependent on the crystallizable fragment (Fc) of IgM, IgM limits BCR 
signaling by binding to the FcμR on B cells; in another, IgM controls 
the development of auto‐reactive B cells in the bone marrow. Thus 
Nguyen et al showed that in the absence of FcμR, expression of 
IgM B cell receptor was increased augmenting tonic signaling, as a 
consequence.43,44
IgM autoantibodies control complement activation, do not 
mediate cytolysis at 37°C and scavenge C3 and C4 complement 
components. IgM inhibits TLR4 activation on endothelial and an‐
tigen‐presenting cells, inhibits leukocyte chemotaxis by binding 
chemokine receptors and production of inflammatory cytokines. 
IgM clears self‐antigens, preventing altered self‐antigen‐induced in‐
flammation, ameliorates inflammatory conditions in murine models 
of complement‐mediated glomerular inflammation, systemic lupus 
erythematosus, arthritis, and atherogenesis, and protects kidneys 
against ischemia‐reperfusion injury and cardiac allografts against re‐
jection. Thus, kidney and heart allografts in patients with high levels 
of natural IgM had better graft survival and lower incidence of acute 
rejection.45‐48
What prevents auto‐reactive antibodies from causing autoim‐
mune disease? One might suppose the antibodies do not achieve 
the concentrations or the affinities of antibodies associated with 
autoimmune disease. But, this explanation is not fully satisfying for 
several reasons. First, germline encoded polyreactive antibodies can 
be driven by affinity maturation to generate antibodies associated 
with such effector functions as the neutralization of viruses and 
the formation of immune complexes.40,49‐53 Second, as we discuss 
presently, polyreactive antibodies do cause tissue injury and disease 
when conditions unrelated to the concentration and affinity of the 
antibodies allow pathogenesis to proceed.54
4.1 | Spatial separation of antibodies and antigen
Although natural autoantibodies potentially react with many dif‐
ferent antigens, the targets available for binding in normal individu‐
als and settings are quite limited. Most natural autoantibodies are 
IgM, which are located inside blood vessels. The potential targets 
are therefore limited to plasma proteins and components on the 
surface of circulating cells and endothelium. Under physiologic con‐
ditions the surfaces of cells are cloaked with glycocalyx that limits 
access of natural IgM and IgG antibodies to cell surface antigens.55 
Furthermore, the attachment of antibodies to cell surface antigens 
can be transient, as autoantigens in plasma cause bound antibodies 
to be shed.56 Plentiful antigen in plasma, especially in monomeric 
form, limits or completely blocks the pathogenicity of circulating 
autoantibodies. To a similar effect, natural autoantibodies bound to 
components of the glycocalyx or to peripheral membrane proteins 
might be shed with the bound antigen, reducing or eliminating path‐
ogenicity of antibody‐antigen interaction.
The biological impact of natural autoantibodies changes pro‐
foundly when cell surfaces are damaged.57 Physical injury, inflam‐
mation, and ischemia cause glycocalyx to be shed,58 exposing 
neoantigens potentially to be recognized by natural autoantibod‐
ies.59‐63 Various neoantigens have been implicated.57 Some antigens 
may be components of the inner plasma membrane trans‐located 
as a result of injury, some may be fixed moieties on plasma mem‐
branes previously covered by glycocalyx. What distinguishes these 
antigens is that they are fixed to the cell surface and not apt to be 
shed with bound antibody. The binding of autoantibodies to these 
fixed antigens causes activation of the complement cascade and 
induces tissue injury. This injury could be considered autoimmune 
disease, as the specific binding of autoantibodies initiates the pro‐
cess. However, this type of autoimmune disease is not a reflection 
F I G U R E  3   Auto‐reactive antibody‐secreting cells in renal 
transplant recipients. B cells capable of secreting antibodies that 
bind to antigens on the surface of intact autologous cells are 
identified by ELISPOT performed using cultured fibroblasts as 
targets (cellular ELISPOT).84 The figure identifies auto‐reactive IgM 
secreting cells in a subject before kidney transplantation
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of loss of tolerance, indeed tolerance was never present. Rather the 
autoimmune disease is brought about by exposure of fixed antigen 
that cannot be shed and not effectively blocked by circulating mo‐
nomeric antigen.
The interaction of natural antibodies with autoantigens "fixed" 
on cell surfaces probably provides an important initial barrier to 
dissemination of microorganisms and toxins.64 Individuals with se‐
lective deficiency of IgM are often found to have severe life threat‐
ening infection 65,66 some manifest autoimmune disease. What is 
important from the present perspective is that antibody‐mediated 
tissue injury and autoimmune disease are not necessarily caused by 
absence of B cell tolerance and B cell tolerance in normal individuals 
does not preclude antibody‐mediated tissue damage.
Spatial separation of antibodies and antigens also determines 
the pathogenicity of IgG. Perhaps the most instructive example can 
be drawn from heated debate about whether or not alloantibodies 
cause the rejection of transplants (see 67‐70 for elaboration of the ar‐
guments). Put briefly, the discovery that allotransplantation almost 
invariably elicits production of alloantibodies 67 was seminal because 
it led to discovery and mapping of the major histocompatibility com‐
plex, as the key determinant of: (a) whether or not a graft would elicit 
alloimmunity; (b) whether or not an allograft would survive; and (c) a 
readily ascertained target of alloantibodies.71,72 Yet, for more than a 
decade after discovery of the MHC, nearly all efforts to show that 
alloantibodies actually cause rejection of tumor and skin allografts 
failed.73,74 Indeed, if alloantibodies had any impact on tumor or skin 
allografts, it was to prolong rather than to shorten graft survival.75 It 
is now appreciated that alloantibodies can repair and protect grafts by 
one or more of several mechanisms, as we later discuss and elsewhere 
review 33,76‐78; however, the beneficial properties of alloantibodies are 
only observed when antibodies fail to exert full effector functions on 
grafts. What prevents alloantibodies from attacking tumor and tissue 
grafts with full effector function is the positioning of endothelium of 
the recipient between the alloantibodies and the graft. Thus, cell and 
tissue grafts residing outside of blood vessels are exposed to concen‐
trations of alloantibodies and complement well below those in plasma. 
In contrast, alloantibodies directly contact the endothelium of organ 
transplants and hence may cause antibody‐mediated rejection.
4.2 | Time
Another, potentially critical factor determining whether antibodies 
will spare or initiate injury upon binding to targets is the kinetics of 
change in antibody concentration. The rate of antibody production, 
delivery to the site of binding, diffusion and rate of removal and the 
condition of cells and tissues in which antibodies bind have consider‐
able impact on the pathogenicity of antibodies. In the laboratory, the 
specificity and function of antibodies are usually tested by adding 
a known amount or dilution of antibody to a target cell or antigen. 
However, in biological systems, autologous cells are never exposed 
suddenly to "peak concentrations" of antibodies; rather concentra‐
tions of antibody increase more or less gradually, even in secondary 
B cell responses, and cells may respond in ways that limit injury.
The relatively gradual increase in antibody concentration is mod‐
eled by addition of sub‐toxic amounts of antibody with or without 
complement to cells in culture. The response to antibody binding 
in this setting varies in part with the antigen: some antigens are 
modulated and some are shed, both of which processes could leave 
less antigen available for binding as the concentration of antibody 
increases. Cells exposed to sub‐toxic amounts of antibodies also 
change in ways that may decrease the impact of further effector 
activity. For example, activation of C3 and C4 lead to covalent at‐
tachment of these proteins to cell surfaces, initially amplifying com‐
plement activation via formation of more convertase complexes. 
However, the bound C3 and C4 are ultimately degraded to catalyt‐
ically inert C3d and C4d polypeptides that continue to occupy and 
thus to block sites with which activated C3 and C4 might react. This 
process may explain how some erythrocytes targeted by autoan‐
tibodies survive.79 As another example, cells on which sub‐lethal 
numbers of membrane attack complexes assemble undergo meta‐
bolic and structural changes that raise the threshold for cytotoxicity 
(reviewed in 80). Thus, unlike Ehrlich's concept of horror autotoxicus, 
the production of autoantibodies is not necessarily inimical to sur‐
vival or even to health.
On the other hand, microorganisms or transplants exposed to 
the blood of immune individuals have no opportunity to adapt to 
antibody binding and complement activation and relatively small 
amounts of specific antibody can be lethal for both. Using organ 
transplants as an example, reperfusion of an allogeneic kidney or 
heart with blood of a recipient who has antibodies specific for the 
transplant can lead to destruction of the transplant in minutes to a 
few hours, a process called hyperacute rejection. For this reason, po‐
tential recipients are screened by cross‐match for antibodies against 
the donor of the graft.81 On the other hand, donor‐specific antibod‐
ies in concentrations that might very well have caused hyperacute 
rejection are not infrequently discovered in recipients with function‐
ing transplants and in this setting cause no dramatic harm to the 
graft (the development of alloantibodies does however signal alloim‐
munity and is associated with the eventual occurrence of rejection 
82). Below we shall discuss some ways organs targeted by antibodies 
can evade injury, a condition called accommodation 80,83; here, we 
use this example to emphasize that antibodies capable of inducing 
the most profound and dramatic immune‐mediate injury do not nec‐
essarily cause pathology and disease. Accordingly, the absence of 
autoimmune disease cannot be taken as proof of immune tolerance.
The impact of the kinetics of immune responses has significance 
also for self‐tolerance. B cells are continuously generated. During 
development and after reaching maturity, B cells with BCR (or BCR 
per se) that recognize self‐antigens are eliminated. However, for rea‐
sons discussed above, the processes that censor the B cell repertoire 
remove many but certainly not all auto‐reactive B cells. For example, 
when we devised a method for identifying and isolating allo‐specific 
B cells, based on the ability of B cells to adhere to and secrete an‐
tibodies that specifically bind allogeneic cells, we found that every 
individual also have auto‐specific B cells that secrete antibodies that 
bind autologous cells.84 What prevents auto‐reactive B cells from 
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inflicting injury? At any point in time, the absence of co‐stimulation 
may prevent autoimmunity. However, at any given time infection or 
injury might generate the co‐stimulatory signals. Under these con‐
ditions, then "tolerance" may reflect the ability of autologous cells 
avoid destruction when a small number of self‐reactive B cells is 
activated.
The rate and conditions of antibody production and hence the 
apparent balance between immunity and tolerance may be subject 
to control by a highly polymorphic region of the genome. TNFRSF13B 
encodes the "transmembrane activator and CAML interactor" 
(TACI), a member of the TNF receptor superfamily. TNFRSF13B 
variants have been found to be associated with common variable 
immunodeficiency 85 and our early work appeared to support that 
idea. We found that the receptor encoded by TNFRSF13B, the "TACI" 
governs plasma cell differentiation and Ig production.86 TACI is the 
receptor for BAFF and APRIL, which upon binding to TACI activates 
BLIMP‐1,87 the transcription factor that causes differentiation of B 
lymphocytes to differentiate into plasma cells 86,88 enabling produc‐
tion of large amounts of antigen‐specific Ig.89 There are however 
several arguments that counter the idea that TNRSF13B mutations 
are exclusively deleterious. Those are: (a) alleles that compromise 
protein function are expressed by 80% of humans and of these 98% 
are healthy; (b) research in our laboratory suggests that heterozy‐
gosity induces resistance to infection by enterobacteria (Cascalho 
et al; submitted); (c) broad surveys of TNFRSF13B genotypes in the 
population reveal an extraordinary degree of polymorphism (951 
TNFRSF13B missense and only 383 synonymous, https ://useast.
ensem bl.org/index.html), a high frequency of dominant negative 
alleles 90,91; and (iv) according to the McDonald‐Kreitman neutral‐
ity index TNFRSF13B is under strong positive selection pressure (in 
contrast to genes encoding HLA‐class I which are under moderate 
purifying pressure).92 These arguments suggest the possibility that 
TNFRSF13B diversity might be maintained by balancing selection.
We propose that TNFRSF13B polymorphisms in a population 
establish a continuum of immune responses varying between two 
extremes: (i) Low performing TNFRSF13B variants evoke antibody 
responses with high affinity at the cost of pathogenicity and auto‐
immunity owing to decreased natural antibodies, heightened com‐
plement activation, high affinity antibodies and enhanced cellular 
immunity; (ii) high performing TNFRSF13B variants evoke antibody 
responses of lower affinity with abundant natural antibodies pro‐
tecting against immune‐mediated injury in part by controlling com‐
plement activation, cellular immunity and inducing resistance to 
immune‐mediated injury (accommodation). Common TNFRSF13B 
polymorphisms determine natural antibody production (IgM and 
IgA) which, in turn regulate complement activation and cellular im‐
munity (De Mattos‐Barbosa et al submitted). Thus, high performing 
TACI variants (a) may allow more complete or accurate censoring of 
autoimmune clones 93; (b) may slow Ab production allowing targeted 
tissues to adapt; and/or (c) TACI may facilitate production of natu‐
ral Ab (IgM) that may facilitate repair/healing.57,94,95 Consistent with 
these ideas, many TNRSF13B variants are associated with aberrant B 
cell selection and with autoimmunity.93 It is also possible that rapid 
generation of antibodies causes pathogenicity when associated with 
a relative deficit of natural Ab.
5  | ACCOMMODATION: THE FIF TH 
DIMENSION OF B CELL TOLER ANCE
The original view prevailing today considers tolerance to be a prop‐
erty of the immune system.22 This view led to seminal theories re‐
garding self‐non‐self discrimination, clonal selection, etc.96 The view 
also fueled many seminal discoveries concerning mechanisms of 
signaling and regulation of lymphocyte functions. Yet, as we men‐
tioned above, the prevailing concepts of tolerance are at best in‐
complete. That is to say that normal individuals have many B cells 
(and T cells) capable of recognizing autologous antigens and appreci‐
able amounts of auto‐reactive antibodies in the circulation. Put in 
another way, the mechanisms of tolerance (clonal deletion, anergy, 
or receptor editing) of B cells that bind self‐antigen fail to eliminate 
all auto‐reactive B cells and auto‐reactive antibody. Accordingly, we 
propose a fifth dimension of tolerance that originates from the inter‐
action between the immunity targets and immunity. Thus, autoim‐
munity while present does not induce immunopathology.
The key concept of the fifth dimension is that absence of im‐
mune pathology results from actions originated both in the target 
tissue and in the immune system which balance protective and 
damaging responses. While aberrant primary development of "for‐
bidden clones" or excessive signaling of B cells and/or T cells may 
cause autoimmunity and autoimmune disease, as often as not the in‐
ception of autoimmunity and immunopathology appears connected 
with immunodeficiency and hypogammaglobulinemia.97‐99 These 
observations might be taken to suggest, iconoclastically, that if the 
mechanisms that censor the BCR repertoire to avoid auto‐reactiv‐
ity functioned too well or too completely, autotoxicus would ensue. 
Various mechanisms have been postulated to explain how immuno‐
deficiency might cause autoimmunity and we shall not undertake a 
critical review these here (reviewed in 100). Rather, we shall discuss 
a mechanism we think merits consideration: "accommodation" or 
tolerance of tissues and organs to immune and inflammatory injury.
5.1 | Accommodation
The phenomenon of accommodation was discovered three dec‐
ades ago when the deliberate transplantation of kidneys into 
ABO‐incompatible recipients hesitantly entered clinical practice 
(see 80 for a more thorough discussion of these observations). Until 
the 1980s, transplantation of organs, particularly kidneys across 
ABO‐blood group barriers (eg a kidney from an individual of blood 
group‐A and/or ‐B transplanted into a recipient with iso‐antibod‐
ies specific for one or both blood group antigens) was generally 
discouraged.101‐103 In up to 85% of recipients, ABO‐incompatible 
kidney transplants either failed immediately to function or under‐
went rejection and failure within a few months.104,105 Graft fail‐
ure was understood to be triggered by the binding of anti‐blood 
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group antibodies, which immune competent adults have 25 to for‐
eign blood group‐A and/or ‐B antigen,106 which is expressed on 
endothelial cells.
Binding of antibodies to graft endothelial cells when the trans‐
plant is first perfused by the recipient can cause activation of com‐
plement which in turn causes a condition called hyperacute rejection 
that destroys the graft in minutes to a few hours (arguably, the most 
severe immune‐mediated pathologic entity). Binding of antibodies to 
graft endothelial cells after the first hours or days causes antibody‐
mediated rejection, the pathology and molecular pathogenesis of 
which differs from hyperacute rejection.76 ABO‐compatible trans‐
plants were less likely to suffer early loss because the recipients are 
tolerant to A‐ or B‐blood group antigens expressed in the graft and 
before transplantation potential recipients are screened by cross‐
matching to assure absence of the antibodies against HLA antigens 
expressed in the graft at the time of transplantation (development 
of these antibodies at later time however does cause antibody‐me‐
diated rejection).
In the 1980s, compelling need for organs for transplantation led 
some to transplant kidneys from donors of blood group A2, which 
is expressed at lower levels than the more common A1, into recipi‐
ents of blood group O.107 The trial was successful as the blood group 
incompatible transplants suffered fewer immediate and late losses. 
However, what was most important to the canonical understanding 
of B cell tolerance was that in most recipients anti‐blood group A 
antibodies returned to the levels detected before transplantation.107 
Thus, in contrast with newborn recipients of cardiac transplants, dis‐
cussed above, these mature recipients clearly did not develop tol‐
erance (as classically understood) to foreign blood group antigens 
expressed the graft.
Reports of occasional successes in ABO‐incompatible transplan‐
tation, especially the results mentioned above led others to explore 
whether deliberate removal of anti‐blood group antibodies from the 
circulation and/or blockade by administration of antigen could pre‐
vent early (hyperacute) rejection and allow some ABO‐incompatible 
transplants to survive and function thereafter.80,105,108‐110 The first 
trials were notably successful. Removal of anti‐blood group antibod‐
ies (and perhaps also the incidental depletion of complement) from 
the circulation prevented hyperacute rejection and the transplants 
survived and functioned at rates approaching those observed for 
ABO‐compatible transplants.
But what was most important for the present discussion was 
that at various times after transplantation, the recipients of the 
ABO‐incompatible kidney transplants had antibodies specific for 
blood group antigens of the donor.83,111‐113 The success of these 
transplants could not be ascribed to the distinct properties of A2 
antigen, as many of the transplants had incompatible A1 or B blood 
groups. Nor were these recipients tolerant, in the conventional 
sense as sometimes, indeed often, the recipients were found to have 
iso‐antibodies directed against donor blood groups at levels equal to 
or greater than those measured prior to transplantation. Especially 
notable too was that the level of these antibodies was unrelated to 
the function of the transplant (see 80 and 113 for review).
The return to the circulation of antibodies specific for endothelial 
cell antigens in a graft without evident impact on the well‐being of 
the graft could reflect one or more of several processes. It is possible 
that synthesis of the saccharide antigen might have changed, per‐
haps owing to generation of antibodies against glycosyl‐tranferases 
or the antigen might have been shed or modulated after transplan‐
tation.111,114,115 However, investigation of antigen expression before 
and after transplantation suggested expression had not changed.83 It 
is possible, too, that antibodies produced after transplantation were 
different in affinity or effector functions.115 No doubt the avidity of 
anti‐donor antibodies in serum does change, but a decrease in avid‐
ity may well reflect preferential absorption of antibodies of the high‐
est avidity to the graft.32 Consistent with that possibility, antibodies 
bound to ABO‐incompatible grafts were found to specifically absorb 
labeled blood group saccharide.116 Thus, the antibody‐antigen reac‐
tions found repeatedly to cause severe types of rejection evidently 
caused little or no injury and functional impairment in some of these 
transplants. We interpreted these findings to suggest that grafts 
might acquire resistance to injury caused by antibodies and com‐
plement and phagocytes, and named this change "accommodation" 
to denote that it was the graft and not the immune response that 
explained the absence of injury.117
Since the initial description, accommodation has been found to 
occur frequently in ABO‐incompatible transplants and sometimes 
in xenografts.76 Accommodation also occurs, although not with‐
out controversy, in organ transplants in recipients with antibodies 
directed against HLA antigens 84,118 as many transplant recipients 
are found to have antibodies specific for graft endothelium in the 
absence of antibody‐mediated rejection. Accommodation is also 
postulated to benefit tumors and facilitate host defense against 
infection.119
The mechanism(s) that enable tissues and organs to sustain nor‐
mal structure and function despite exposure to antibodies specific 
for surface antigens has been the subject of much investigation 
and some debate. There is general agreement that cells, tissues and 
organs targeted by antibodies must have at least normal if not in‐
creased ability to resist complement‐mediated cytotoxicity.120 Such 
resistance depends on expression of cytoprotective genes and ac‐
tivation of cytoprotective pathways.121‐123 However, more recent 
work indicates that if inhibition of cytotoxicity is essential for accom‐
modation, it is also not sufficient. Accommodation requires repair of 
immune mediated injury and structural and metabolic changes that 
provide ongoing resistance to injury.80,124 These changes transpire 
over days to weeks.78,125
The set of mechanisms that overcome antibody‐mediated in‐
jury and resist subsequent injury are yet to be fully elucidated. 
We shall discuss one property in the section that follows. What is 
important for the present is that these mechanisms limit the im‐
pact of the most dramatic and severely toxic immune reactions on 
normal cells, tissues and organs. Accommodation thus has several 
implications vital to the understanding of B cell tolerance. First, if 
B cell responses generate antibodies that can mediate cytotoxicity 
but the antibodies cause little or no injury or dysfunction then 
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injury and organ dysfunction could offer misleading indices of 
tolerance. Transplant recipients who discontinue immunosuppres‐
sive therapy and do not suffer rejection are sometimes postulated 
to have spontaneously developed tolerance to their grafts.126‐129 
Some of these "tolerant" recipients have antibodies in the circu‐
lation specific for antigens in the graft. Likewise, individuals with 
"autoimmune disease" with circulating autoantibodies sometimes 
have no overt manifestations of disease. These individuals may 
have accommodation rather than non‐pathogenic B cell responses. 
Second, and still more important is the possibility that an untow‐
ard event might cause loss of structural integrity and metabolic 
changes that prevent injury caused by ongoing autoimmunity or 
alloimmunity. Yet, investigation of autoimmune‐ and alloimmune‐
mediated disease usually focuses on changes in the immune re‐
sponse rather than susceptibility to injury.
5.2 | Clearance of antibodies
Investigation of B cell responses and B cell tolerance usually relies on 
the assay of circulating antibodies specific for the antigen or set of 
antigens of interest. If the antigen of interest is uncertain, antibodies 
against other antigens can be assayed as surrogates. Transplantation 
provides a clear example of the opportunity and challenges regard‐
ing B cell tolerance. Tolerance to the graft is the clinical ideal out‐
come, as the tolerant recipient is freed of the requirement for and 
side effects of immunosuppressive therapy. Indeed, as mentioned 
above, some transplant recipients are believed to have spontane‐
ously acquired tolerance to their graft, as cessation of immunosup‐
pression does not lead to rejection.126‐130
One might expect that tolerance to a transplant would be read‐
ily identified. In experimental systems, transplantation reliably gen‐
erates immunity to allogeneic major histocompatibility antigens. 
Antigens encoded in the major histocompatibility complex are highly 
immunogenic (immunogenic enough that MHC was originally iden‐
tified and mapped using allo‐antisera) and the antibodies elicited by 
transplantation are quite specific (allo‐antisera for laboratory use 
are generated by transplantation). Moreover, assays for anti‐HLA 
antibodies and donor‐specific antibodies have been perfected over 
decades and standardized for application in clinical laboratories 
and overwhelming evidence indicates that alloantibodies provide 
the most sensitive and specific predictor of alloimmunity and re‐
jection.81 Nevertheless, the absence of donor‐specific antibodies in 
the blood of a transplant recipient is not taken to indicate tolerance 
and no approach yet devised reliably identifies B cell tolerance to a 
transplant antigen.
What might well pose the preeminent obstacle to identifying 
B cell tolerance to self and to transplants is that normal cells and 
tissues potentially can absorb enormous amounts of antibody 
from blood 32 therefore, absence of antibody in the blood against 
a given cellular antigen could reflect absorption rather than spe‐
cific non‐production. We have discussed this problem in various 
contexts,80,123 but we are scarcely the first to do so. Landsteiner 26 
considered the absorption of antibody to antigen and removal from 
the circulation to be key hurdle to understanding the governance of 
antibody production.
Work in transplantation, where the concentration of antibodies 
specific for foreign antigens can be ascertained, confirms the extent 
of the problem. In ABO‐incompatible organ transplantation, the 
assay of antibodies specific for foreign blood group antigens often 
reveals that reperfusion of the organ causes substantial if not full 
depletion of iso‐antibodies (see 80 for review). Indeed, perfusion of 
an isolated organ effectively depletes natural antibodies directed 
against xenografts.131 Indeed, the main limitation to depletion of 
antibodies in this way is that activation of complement causes con‐
striction of and injury to blood vessels, in turn limiting the period of 
perfusion to about 30 min in this extreme model in which regulation 
of complement is impaired.132 The implications for investigation of 
B cell responses and tolerance in transplantation and other condi‐
tions in which antigen is plentiful are that antibodies of the highest 
avidity and antibodies specific for the most plentiful antigens may 
be preferentially depleted by binding to cellular antigens, leaving in 
the blood antibodies of lower avidity and/or directed against scarce 
antigens.
There is another facet of the phenomenon of antibody depletion 
that may be pertinent to B cell responses and to tolerance. The abil‐
ity of cells to remove antibody from blood or extracellular fluid varies 
in the part with the antigen. Investigation of cells in culture reveals 
that antigens expressed on plasma membranes vary in response to 
bound antibodies—some antigens appear inured to bound antibody 
and expression continues,56,133 other antigens are modulated and 
the bound antibodies are either metabolized or released intact from 
the cells.134,135 However, antibodies bound in vivo are more robustly 
depleted and metabolized, suggesting that cells in culture may fail to 
fully represent the fate of antigen and antibody. We suspect that the 
difference is likely owed to the impact of complement. Complement 
activation on cell surfaces triggers endocytosis, which removes com‐
plement complexes and potentially bound antibody.136
The process of antibody clearance has important implications 
for understanding of B cell responses and tolerance. Bound anti‐
bodies that activate complement might be more readily and fully 
cleared than antibody that does not activate complement or anti‐
bodies bound when complement is inhibited. Thus, autoantibodies 
or alloantibodies that bind to healthy cells and activate sub‐lytic 
amounts of complement might be effectively depleted and assays 
of the blood might thus suggest that little or no antibody has been 
produced. On the other hand, if cellular functions are impaired 
or if cells are injured, the ability to take up and metabolize anti‐
body decreases and autoantibody or alloantibody levels in blood 
might increase. These scenarios are the opposite of what is usually 
envisioned as the immune pathogenesis of disease and it is not 
clear whether and when this series of events can occur. Surveys 
of recipients of kidney transplants reveal that donor‐specific anti‐
bodies often appear after rather than before episodes of rejection 
are detected,33 suggesting the possibility that antibody absorption 
impaired detection of immunity until the graft had been injured 
by rejection. This process is also pertinent to accommodation, as 
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resistance to complement‐mediated injury probably depends in 
part on efficient clearance of complement complexes from cell 
surfaces.
6  | CONCLUDING REMARKS
The prevailing view of B cell tolerance as an active process that 
obviates or at least minimizes specific recognition of self has had 
immense value. This view fueled investigation of the cellular basis 
of immunity and clonal selection as a process that enables robust 
protective responses that spare autogenous cells (for a review 22). 
The original view of B cell tolerance "in the three dimensions," as we 
put it gave impetus to understanding how co‐stimulation and ger‐
minal center reactions regulate the specificity of B cell responses. 
Yet, perhaps inevitably, models focusing on individual physiologic 
systems can over‐simplify and in some cases distort understanding 
of processes that support well being in vivo. The original view of B 
cell tolerance may exemplify that problem.
Autoantibodies and the B cells that produce autoantibodies, 
while not understood as fully as B cells that produce antibodies di‐
rected at foreign antigens, confer obvious benefits in host defense, 
repair of injury, and immune regulation. Whether the existence of 
self‐reactive B cells reflects "leakiness" or an evolved bypass of the 
processes that censor lymphocyte repertoires cannot be addressed 
today. What must be countenanced, however, is that all healthy in‐
dividuals have auto‐reactive antibodies and many individuals with 
inherited immunodeficiency diseases lack these antibodies, in part 
or entirely. Accordingly, any consideration of how tolerance influ‐
ences well‐being must allow that depletion of all auto‐reactive B 
cells would leave an individual at greater biological jeopardy than 
would imperfect or incomplete depletion of auto‐reactive B cells.
To account for the contribution of autoantibodies to overall fit‐
ness, we discuss two further dimensions of B cell tolerance. One di‐
mension focuses on the localization of antigens recognized and the 
period of time during which antibodies are produced. This dimension 
views natural autoantibodies as intrinsic to the normal immune sys‐
tem. Natural autoantibodies may or may not bind infectious organ‐
isms but they reliably bind injured cells, recognizing antigens that are 
either hidden or displayed in ways that binding of antibodies does 
not disrupt tissue vitality and function. When infection or injury oc‐
curs, vascular and lymphatic surfaces appear immediately to display 
epitopes recognized by natural antibodies. Although natural autoan‐
tibodies can have distinct properties, such as poly‐reactivity and en‐
coding by germline V region gene segments, understanding how the 
antibodies contribute to well‐being requires more attention to the 
nature and location of the antigens recognized. Such attention will 
hopefully explain how the same antibodies that confer protection or 
initiate repair in some settings induce tissue injury in others.57 The 
location of the antigen on vascular cells facilitates the containing of 
infectious organisms and toxins with a segment of a tissue; but, it 
also allows natural antibodies to participate in the ischemia‐reperfu‐
sion injury that afflicts entire transplants.64
Since the physiologic actions of natural IgM and IgG autoanti‐
bodies are in part confined to surfaces of endothelium and circulat‐
ing cells the B cells that produce those antibodies need not respond 
to antigen by massively increasing production. However, excess of 
natural autoantibodies potentially could induce injury. Therefore, 
regulation of these B cells differs from the regulation of B cells that 
produce elicited IgG. Nevertheless, regulation does ultimately em‐
ploy clonal deletion, selection and/or receptor editing.30,137
Yet a fifth dimension of B cell tolerance is put forth to allow for 
the possibility that some autoantibodies will escape control and 
potentially induce harm. Such noxious autoantibodies might be the 
products of B cells that escaped control by the conventional (three 
dimensions of tolerance) or of B cells that produce natural autoan‐
tibodies but for some reason do so in excess. What we see more or 
less universally in transplantation and perhaps might see in normal 
physiology is that excess or untoward antibody binding to autol‐
ogous cells does not inflict irreversible injury because the cellular 
targets can adapt to antibody binding, to activation of complement, 
opsonization and perhaps other noxious events by acquiring ability 
to repair damaged surfaces and resist cytotoxicity. That is, tissues 
can become tolerant of immunity as immunity is not entirely tolerant 
to self. We call this condition "accommodation."
Since all normal individuals have circulating autoantibodies and 
since complement is continuously activated in normal blood (both by 
alternative and classical pathways), we suspect the normal, baseline 
state of endothelium and circulating cells includes some measure 
of accommodation. On the other hand, the posture of accommo‐
dation likely subsides in endothelial and hematopoietic cells stored 
and cultivated outside normal blood and that makes the cells more 
susceptible to acute injury. We have some understanding of how 
accommodation is induced and the changes it embodies but rather 
little about how it subsides. However, under conditions of infection, 
accommodation probably subsides quickly, allowing complement 
and leukocytes to sequester organisms and toxins in vascular seg‐
ments. A particularly dramatic example of the subsiding of accom‐
modation might be the newly transplanted organ. Only during the 
first day after transplantation is an organ susceptibility to the dra‐
matic and devastating condition known as "hyperacute rejection" 
induced by antibody binding and complement activation. After a few 
days, transplants acquire at least some resistance so that while anti‐
bodies and complement induce rejection (antibody‐mediated rejec‐
tion), the pathology and course are distinct and notably less dramatic 
and severe.
The perspective this fifth dimension brings raises the possibil‐
ity that autoimmune disease or transplant rejection might occur in 
some cases when accommodation subsides or fails. Whether or not 
and how often that pathogenic mechanism applies is unknown; but 
nonetheless important because it opens a window onto new thera‐
peutic targets and strategies. And, regardless of whether one pre‐
fers the long‐standing definition of tolerance or a broader view that 
includes accommodation, the perspective reinforces the need to 
study B cells and the targets of antibodies and not just antibodies to 
achieve fuller insight into immunity, tolerance, and disease.
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